CR9918A - Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina - Google Patents

Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina

Info

Publication number: CR9918A
Authority: CR; Costa Rica
Prior art keywords: antigonist; pirazolo; pyrimidinyl; alpha; derivatives
Prior art date: 2005-09-30

Application number

CR9918A

Other languages

English (en)

Inventor

Frank Hossner

Original Assignee

Neurocrine Biosciences Inc

Bayer Cropsciense Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-30

Filing date

2008-04-23

Publication date

2009-02-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-23 Application filed by Neurocrine Biosciences Inc, Bayer Cropsciense Ag filed Critical Neurocrine Biosciences Inc

2009-02-03 Publication of CR9918A publication Critical patent/CR9918A/es

Links

-1 PYRIMIDINYL Chemical class 0.000 title 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title 1
239000003488 releasing hormone Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CR9918A 2005-09-30 2008-04-23 Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina CR9918A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0519957.5A GB0519957D0 (en)	2005-09-30	2005-09-30	Chemical compound

Publications (1)

Publication Number	Publication Date
CR9918A true CR9918A (es)	2009-02-03

Family

ID=35395069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR9918A CR9918A (es)	2005-09-30	2008-04-23	Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina

Country Status (21)

Country	Link
US (1)	US7879862B2 (es)
EP (2)	EP1802627B1 (es)
JP (2)	JP4901744B2 (es)
KR (2)	KR20070088621A (es)
CN (1)	CN101273043B (es)
AR (2)	AR051461A1 (es)
AU (2)	AU2005295353B2 (es)
BR (1)	BRPI0616767A2 (es)
CA (2)	CA2584567C (es)
CR (1)	CR9918A (es)
EA (1)	EA200801000A1 (es)
GB (1)	GB0519957D0 (es)
IL (1)	IL190225A0 (es)
MA (1)	MA29850B1 (es)
NO (2)	NO20072541L (es)
NZ (1)	NZ554082A (es)
PE (2)	PE20060586A1 (es)
RU (1)	RU2007118683A (es)
TW (2)	TW200626599A (es)
UA (1)	UA92756C2 (es)
WO (2)	WO2006044958A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196078B2 (en)	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY143499A (en) *	2003-12-22	2011-05-31	Sb Pharmco Inc	Crf receptor antagonist and methods relating thereto
GB0519957D0 (en) *	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US7579360B2 (en)	2005-06-09	2009-08-25	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en)	2005-06-09	2009-08-11	Bristol-Myers Squibb Company	Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en)	2005-09-30	2012-01-03	Smithkline Beecham (Cork) Limited	Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
GB0525068D0 (en)	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
US8119658B2 (en)	2007-10-01	2012-02-21	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101932583A (zh)	2007-12-19	2010-12-29	沃泰克斯药物股份有限公司	用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
US8431603B2 (en)	2008-04-15	2013-04-30	Eisai R&D Management Co., Ltd.	3-phenylpyrazolo[5,1-b]thiazole compounds
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
AR078521A1 (es) *	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
JPWO2011043387A1 (ja) *	2009-10-08	2013-03-04	エーザイ・アール・アンド・ディー・マネジメント株式会社	ピラゾロオキサゾール化合物
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (en)	2010-02-01	2014-07-23	Novartis AG	Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
US8835444B2 (en) *	2010-02-02	2014-09-16	Novartis Ag	Cyclohexyl amide derivatives as CRF receptor antagonists
UY34094A (es)	2011-05-27	2013-01-03	Novartis Ag	Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
WO2013074641A1 (en)	2011-11-16	2013-05-23	Array Biopharma Inc.	Piperidinyl- substituted cyclic ureas as gpr119 modulators
JP2015516979A (ja) *	2012-04-23	2015-06-18	ホルスボールマッシュマイヤーニューロケミーゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒＮｅｕｒｏｃｈｅｍｉｅＧｍｂｈ	Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
TW201348235A (zh)	2012-05-03	2013-12-01	Novartis Ag	作爲格瑞啉受體促效劑之３－螺環哌啶衍生物
GB201210686D0 (en)	2012-06-15	2012-08-01	Holsboermaschmeyer Neurochemie Gmbh	V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en)	2013-06-17	2013-07-31	Max Planck Innovation Gmbh	Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
IL296683B2 (en)	2014-01-21	2023-12-01	Neurocrine Biosciences Inc	Preparations for the treatment of congenital adrenal hyperplasia
AU2015208205B2 (en) *	2014-01-22	2019-12-05	Curovir Ab	Pyrazolo[1,5-a]pyrimidines as antiviral compounds
CN110446495B (zh)	2017-02-17	2023-09-05	特维娜有限公司	含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
US10357493B2 (en)	2017-03-10	2019-07-23	Selenity Therapeutics (Bermuda), Ltd.	Metalloenzyme inhibitor compounds
CN120284862A (zh)	2018-12-07	2025-07-11	纽罗克里生物科学有限公司	用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
US12383536B2 (en)	2019-09-27	2025-08-12	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods of use
CR20220325A (es)	2019-12-20	2022-08-19	Tenaya Therapeutics Inc	Fluoroalquil-oxadiazoles y sus usos
JP2023546729A (ja) *	2020-10-27	2023-11-07	トレベナ・インコーポレイテッド	デルタオピオイドモジュレーターの結晶形及び非晶形
KR20240016950A (ko)	2021-05-04	2024-02-06	테나야 테라퓨틱스, 인코포레이티드	대사 질환 및 hfpef의 치료에 사용하기 위한 2-플루오로알킬-1,3,4-옥사디아졸-5-일-티아졸, hdac6 억제제

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4605642A (en)	1984-02-23	1986-08-12	The Salk Institute For Biological Studies	CRF antagonists
WO1995035298A1 (en)	1994-06-21	1995-12-28	Otsuka Pharmaceutical Factory, Inc.	PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
US6664261B2 (en)	1996-02-07	2003-12-16	Neurocrine Biosciences, Inc.	Pyrazolopyrimidines as CRF receptor antagonists
CZ244598A3 (cs)	1996-02-07	1998-10-14	Janssen Pharmaceutica N.V.	Pyrazolopyrimidiny jako antagonisty CRF receptoru
NZ333777A (en) *	1996-07-24	2000-07-28	Du Pont Pharm Co	(1,5-a) pyrazolo and triazole triazines and pyrimidines
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US6060478A (en) *	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
ATE375344T1 (de)	1996-07-24	2007-10-15	Bristol Myers Squibb Pharma Co	Azolotriazine und pyrimidine
JPH10101672A (ja)	1996-08-06	1998-04-21	Otsuka Pharmaceut Factory Inc	アデノシン増強剤
JPH10101671A (ja)	1996-08-08	1998-04-21	Otsuka Pharmaceut Factory Inc	一酸化窒素合成酵素阻害剤
CZ68199A3 (cs)	1996-08-28	1999-11-17	Pfizer Inc.	6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
SI1344779T1 (sl)	1998-01-28	2006-02-28	Bristol Myers Squibb Pharma Co	Azolo-pirimidini
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
WO2000044754A1 (en)	1999-01-29	2000-08-03	Sumitomo Chemical Company, Limited	Fat accumulation inhibitory agents
AU4203500A (en) *	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
HUP0202678A3 (en)	1999-09-30	2004-06-28	Pfizer	Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
PL354982A1 (en)	1999-09-30	2004-03-22	Neurogen Corporation	Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
CO5271670A1 (es) *	1999-10-29	2003-04-30	Pfizer Prod Inc	Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
CA2446514A1 (en) *	2001-04-30	2002-11-07	Glaxo Group Limited	Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
JP2004533465A (ja) *	2001-06-12	2004-11-04	グラクソ　グループ　リミテッド	コルチコトロピン放出因子アンタゴニスト
GB0117396D0 (en) *	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
DE60319820T2 (de)	2002-06-04	2009-03-26	Schering Corp.	Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
ATE359782T1 (de) *	2003-01-16	2007-05-15	Sb Pharmco Inc	Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
EP1608652A1 (en)	2003-03-31	2005-12-28	Vernalis (Cambridge) Limited	Pyrazolopyrimidine compounds and their use in medicine
GB0308208D0 (en) *	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
US20070021429A1 (en) *	2003-04-09	2007-01-25	Yves St-Denis	Condensed n-heterocyclic compounds and their use as crf receptor antagonists
MY143499A (en)	2003-12-22	2011-05-31	Sb Pharmco Inc	Crf receptor antagonist and methods relating thereto
US20070293511A1 (en) *	2003-12-22	2007-12-20	Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation	Crf Receptor Antagonists and Methods
DE102004008807A1 (de) *	2004-02-20	2005-09-08	Bayer Cropscience Ag	Pyrazolopyrimidine
EP1802621B1 (en) *	2004-10-19	2009-05-06	SmithKline Beecham (Cork) Limited	Crf receptor antagonists and methods relating thereto
GB0519957D0 (en) *	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US8088779B2 (en) *	2005-09-30	2012-01-03	Smithkline Beecham (Cork) Limited	Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

2005
- 2005-09-30 GB GBGB0519957.5A patent/GB0519957D0/en not_active Ceased
- 2005-10-17 TW TW094136095A patent/TW200626599A/zh unknown
- 2005-10-17 PE PE2005001219A patent/PE20060586A1/es not_active Application Discontinuation
- 2005-10-17 AR ARP050104337A patent/AR051461A1/es not_active Application Discontinuation
- 2005-10-19 US US11/576,957 patent/US7879862B2/en active Active
- 2005-10-19 RU RU2007118683/04A patent/RU2007118683A/ru not_active Application Discontinuation
- 2005-10-19 EP EP05818308A patent/EP1802627B1/en not_active Expired - Lifetime
- 2005-10-19 KR KR1020077008794A patent/KR20070088621A/ko not_active Ceased
- 2005-10-19 WO PCT/US2005/037576 patent/WO2006044958A1/en not_active Ceased
- 2005-10-19 CA CA2584567A patent/CA2584567C/en not_active Expired - Fee Related
- 2005-10-19 AU AU2005295353A patent/AU2005295353B2/en not_active Ceased
- 2005-10-19 NZ NZ554082A patent/NZ554082A/en not_active IP Right Cessation
- 2005-10-19 JP JP2007537996A patent/JP4901744B2/ja not_active Expired - Lifetime
2006
- 2006-09-28 CN CN2006800355977A patent/CN101273043B/zh not_active Expired - Fee Related
- 2006-09-28 AR ARP060104269A patent/AR056104A1/es not_active Application Discontinuation
- 2006-09-28 PE PE2006001185A patent/PE20070845A1/es not_active Application Discontinuation
- 2006-09-28 CA CA002624699A patent/CA2624699A1/en not_active Abandoned
- 2006-09-28 UA UAA200803939A patent/UA92756C2/ru unknown
- 2006-09-28 WO PCT/EP2006/009531 patent/WO2007039264A1/en not_active Ceased
- 2006-09-28 KR KR1020087007620A patent/KR20080063760A/ko not_active Withdrawn
- 2006-09-28 JP JP2008532687A patent/JP2009510004A/ja not_active Ceased
- 2006-09-28 AU AU2006298995A patent/AU2006298995B2/en not_active Ceased
- 2006-09-28 BR BRPI0616767-5A patent/BRPI0616767A2/pt not_active IP Right Cessation
- 2006-09-28 EP EP06805979A patent/EP1934222B1/en active Active
- 2006-09-28 TW TW095135886A patent/TW200745121A/zh unknown
- 2006-09-28 EA EA200801000A patent/EA200801000A1/ru unknown
2007
- 2007-05-16 NO NO20072541A patent/NO20072541L/no not_active Application Discontinuation
2008
- 2008-03-17 IL IL190225A patent/IL190225A0/en unknown
- 2008-04-04 MA MA30813A patent/MA29850B1/fr unknown
- 2008-04-23 NO NO20081941A patent/NO20081941L/no not_active Application Discontinuation
- 2008-04-23 CR CR9918A patent/CR9918A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN101273043A (zh)	2008-09-24
TW200745121A (en)	2007-12-16
KR20080063760A (ko)	2008-07-07
EP1802627B1 (en)	2012-08-29
EA200801000A1 (ru)	2009-02-27
EP1802627A1 (en)	2007-07-04
MA29850B1 (fr)	2008-10-03
GB0519957D0 (en)	2005-11-09
AU2005295353B2 (en)	2012-01-12
JP2009510004A (ja)	2009-03-12
US20080194589A1 (en)	2008-08-14
CA2584567C (en)	2013-04-30
PE20070845A1 (es)	2007-08-25
PE20060586A1 (es)	2006-09-20
AU2005295353A1 (en)	2006-04-27
CA2584567A1 (en)	2006-04-27
AU2006298995A1 (en)	2007-04-12
AR051461A1 (es)	2007-01-17
US7879862B2 (en)	2011-02-01
JP4901744B2 (ja)	2012-03-21
TW200626599A (en)	2006-08-01
WO2006044958A1 (en)	2006-04-27
WO2007039264A1 (en)	2007-04-12
BRPI0616767A2 (pt)	2011-06-28
RU2007118683A (ru)	2008-11-27
CA2624699A1 (en)	2007-04-12
IL190225A0 (en)	2009-09-22
NZ554082A (en)	2010-12-24
EP1934222B1 (en)	2012-07-25
WO2006044958A8 (en)	2006-06-08
AU2006298995B2 (en)	2012-06-14
NO20081941L (no)	2008-04-23
JP2008517067A (ja)	2008-05-22
CN101273043B (zh)	2011-08-03
AR056104A1 (es)	2007-09-19
EP1934222A1 (en)	2008-06-25
KR20070088621A (ko)	2007-08-29
UA92756C2 (ru)	2010-12-10
NO20072541L (no)	2007-06-25

Publication	Publication Date	Title
CR9918A (es)	2009-02-03	Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina
MA28824B1 (fr)	2007-08-01	Derives de pyrimidine
MA28813B1 (fr)	2007-08-01	Derives de pyrimidine
ZA200800353B (en)	2008-12-31	Pyrazine derivatives useful as adenosine receptor antagonists
BRPI0716936A2 (pt)	2013-09-17	derivados de adenosina como antigonistas de receptor de a2a
NL2000323A1 (nl)	2007-06-21	Pyrimidine-derivaten.
EP1724267A4 (en)	2009-04-22	pyrimidine derivative
IL192310A0 (en)	2008-12-29	Substituted aniline derivatives useful as histamine h3 antagonists
CU23886B1 (es)	2013-04-19	Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
EP2154967A4 (en)	2010-05-19	Pyrimidine derivatives
ATE481409T1 (de)	2010-10-15	Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
BRPI0911688A2 (pt)	2015-07-28	"compostos de pirimidina, composições e métodos de uso"
DOP2007000068A (es)	2007-10-31	Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
EP1890703A4 (en)	2010-11-03	pyrimidine
DK1995242T3 (da)	2012-12-17	Hidtil ukendt 1,2,3,4-tetrahydroquinoxalinderivat med glucocorticoidreceptorbindingsaktivitet.
ZA200708187B (en)	2008-11-26	Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-D]pyrimidine derivatives
IL196671A0 (en)	2009-11-18	Substituted imidazolone derivatives, preparation and uses
CR20130209A (es)	2013-09-19	Derivados de carboxamida como antagonistas del receptor muscarinico
GB0525083D0 (en)	2006-01-18	Pyrimidine derivatives
ATE454377T1 (de)	2010-01-15	2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE538130T1 (de)	2012-01-15	Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
DE602006010508D1 (de)	2009-12-31	Substituierte triazolderivate als oxytocinantagonisten
ATE421511T1 (de)	2009-02-15	Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE487718T1 (de)	2010-11-15	Substituierte bizyklische pyrimidonderivate
PT1355639E (pt)	2006-06-30	Derivados de carboestirilo substituidos como agonistas do subtipo de receptores 5-ht1a

Legal Events

Date	Code	Title	Description
2013-04-05	FA	Abandonment or withdrawal (granting procedure)